• F P Bymaster, H E Shannon, K Rasmussen, N W DeLapp, J S Ward, D O Calligaro, C H Mitch, C Whitesitt, T S Ludvigsen, M Sheardown, M Swedberg, T Rasmussen, P H Olesen, L Jeppesen, P Sauerberg, and A Fink-Jensen.
• Neuroscience Research Division, Lilly Research Laboratories, Indianapolis, IN 46285-0510, USA.
• Life Sci. 1999 Jan 1; 64 (6-7): 527-34.

AbstractThe role of muscarinic receptors in schizophrenia was investigated using the muscarinic agonist PTAC. PTAC was highly selective for muscarinic receptors, was a partial agonist at muscarinic M2/M4 receptors and an antagonist at M1, M3 and M5 receptors. PTAC was highly active in animal models predictive of antipsychotic behavior including inhibition of conditioned avoidance responding in rats and blockade of apomorphine-induced climbing behavior in mice. d-Amphetamine-induced Fos expression in rat nucleus accumbens was inhibited by PTAC, thus directly demonstrating the ability of PTAC to modulate DA activity. In electrophysiological studies in rats, PTAC acutely inhibited the firing of A10 DA cells and after chronic administration decreased the number of spontaneously firing DA cells in the A10 brain area. However, PTAC did not appreciably alter the firing of A9 DA cells. Thus, PTAC appears to have novel antipsychotic-like activity and these data suggest that muscarinic compounds such as PTAC may represent a new class of antipsychotic agents.

50 keywords...

hide…